Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center
Articles
After Progression on PIK3CAi Therapy: MTOR Inhibition
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Significance of PIK3CA Mutation in HR+ Breast Cancer
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Mechanisms of Resistance to CDK4/6 Inhibitors
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
CDK4/6 Clinical Trial Survival Data Impact
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
CDK4/6 Inhibition in HR+ Metastatic Breast Cancer
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Next-Generation Sequencing: Triple Negative Breast Cancer
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Phase 3 ASCENT Regimen Accelerated Approval
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
ASCO New Data: PARP Inhibitors
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
KEYNOTE-355 Regimen’s Role in Treatment Paradigm
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
PD-L1 Testing Standard of Practice
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Perspectives on Recent Progress: Program Overview
Joyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center;Dejan Juric, MD, Massachusetts General Hospital;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Denise Yardley, MD, Tennessee Oncology
July 14th 2020Read More
Educational Tools for Possible Drug-Induced ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Management of Patients Who Develop ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Changes in Treatment Goals due to Drug Induced ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Risk of ILD as a Class Effect and Identifying ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Risks for Developing ILD in Gastrointestinal Cancer Studies
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Role of Antibody Drug Conjugates and Personal Experience
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Patient Management and Educational Tools for ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Rate of ILD and Monitoring Parameters
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Personal Experience with Drug-Induced ILD
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Potential Risk of Drug-Induced Interstitial Lung Disease
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Patient Management upon Developing ILD and Education
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Patient Factors for Developing ILD and Personal Experience
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Managing Patient Symptoms and Clinician Education
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
CDK 4/6 Inhibitors and Identifying ILD in Patients
Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center;Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center;Axel Grothey, MD, West Cancer Center, University of Tennessee;Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins;Tanios Bekaii-Saab, MD, FACP, Mayo Clinic
June 30th 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
